Key result
DIAD investigators defend reported silent ischemia prevalence in asymptomatic type 2 diabetes against overestimation claims.
Why the study?
The prevalence and predictors of silent ischemia in asymptomatic patients with type 2 diabetes were not well characterized.
Answers are grounded in this paper and cite their sources.
Supports DIAD prevalence validity in asymptomatic T2D; leaves open whether screening improves outcomes.
The DIAD study was designed to investigate the prevalence and predictors of silent ischemia, specifically in asymptomatic patients with type 2 diabetes (1), who often present with advanced coronary artery disease (CAD) without prior angina. The DIAD study did not compare the prevalence of asymptomatic CAD in diabetic and nondiabetic patients. Although the relative prevalence of asymptomatic CAD in nondiabetic patients otherwise well-matched for cardiac risk factors is of interest, it will require a much larger study. Bhalodkar and Blum (2) express concern that the prevalence of silent ischemia in DIAD might be overestimated. We believe this to be unlikely. All single-photon emission–computed tomography …
No takes yet. Share an insight, caveat, or question.
Wackers et al. (2005) conducted a letter in Type 2 diabetes. Silent myocardial ischemia was evaluated on Prevalence and predictors of silent ischemia. The authors argue that the prevalence of silent ischemia in asymptomatic patients with type 2 diabetes in the DIAD study was unlikely to be overestimated.
Synapse has enriched 10 related papers. Consider them for comparative context: